Insider · CIK 0001587477
James Karrels
Files at MGNX (MACROGENICS INC). First filing -, latest -.
In brief
James Karrels files SEC Form 4 as CFO at MGNX (MACROGENICS INC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; James Karrels has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 4, 2024 | MGNX MACROGENICS INC | 30,000 0.05% of outstanding | $615k | Mar 4, 2024 | none |
Transactions
Every row this insider has filed, 19 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 15, 2026 | MGNX MACROGENICS INC | MOption exercise Common Stock | +14,999 | - | - | 211,827 | Feb 17, 2026 |
| Feb 15, 2026 | MGNX MACROGENICS INC | FTax withholding Common Stock | -5,790 | $1.71 | $9,901 | 206,037 | Feb 17, 2026 |
| Feb 15, 2026 | MGNX MACROGENICS INC | MOption exercise Restricted Stock Unitderivative | -14,999 | $0.00 | $0 | 0 | Feb 17, 2026 |
| Feb 12, 2026 | MGNX MACROGENICS INC | AGrant or award Employee Stock Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Feb 17, 2026 |
| Feb 12, 2026 | MGNX MACROGENICS INC | AGrant or award Restricted Stock Unitderivative | +25,000 | $0.00 | $0 | 25,000 | Feb 17, 2026 |
| Feb 7, 2026 | MGNX MACROGENICS INC | MOption exercise Common Stock | +6,334 | - | - | 193,135 | Feb 10, 2026 |
| Feb 7, 2026 | MGNX MACROGENICS INC | FTax withholding Common Stock | -2,446 | $1.81 | $4,427 | 190,689 | Feb 10, 2026 |
| Feb 8, 2026 | MGNX MACROGENICS INC | MOption exercise Common Stock | +9,999 | - | - | 200,688 | Feb 10, 2026 |
| Feb 8, 2026 | MGNX MACROGENICS INC | FTax withholding Common Stock | -3,860 | $1.81 | $6,987 | 196,828 | Feb 10, 2026 |
| Feb 7, 2026 | MGNX MACROGENICS INC | MOption exercise Restricted Stock Unitderivative | -6,334 | $0.00 | $0 | 12,666 | Feb 10, 2026 |
| Feb 8, 2026 | MGNX MACROGENICS INC | MOption exercise Restricted Stock Unitderivative | -9,999 | $0.00 | $0 | 9,999 | Feb 10, 2026 |
| Feb 15, 2025 | MGNX MACROGENICS INC | MOption exercise Common Stock | +14,998 | $0.00 | $0 | 192,591 | Feb 19, 2025 |
| Feb 15, 2025 | MGNX MACROGENICS INC | FTax withholding Common Stock | -5,790 | $2.56 | $15k | 186,801 | Feb 19, 2025 |
| Feb 15, 2025 | MGNX MACROGENICS INC | MOption exercise Restricted Stock Unitderivative | -14,998 | $0.00 | $0 | 14,999 | Feb 19, 2025 |
| Feb 8, 2025 | MGNX MACROGENICS INC | MOption exercise Common Stock | +10,002 | - | - | 181,454 | Feb 11, 2025 |
| Feb 8, 2025 | MGNX MACROGENICS INC | FTax withholding Common Stock | -3,861 | $2.60 | $10k | 177,593 | Feb 11, 2025 |
| Feb 7, 2025 | MGNX MACROGENICS INC | AGrant or award Employee Stock Option (right to buy)derivative | +113,000 | $0.00 | $0 | 113,000 | Feb 11, 2025 |
| Feb 7, 2025 | MGNX MACROGENICS INC | AGrant or award Restricted Stock Unitderivative | +19,000 | $0.00 | $0 | 19,000 | Feb 11, 2025 |
| Feb 8, 2025 | MGNX MACROGENICS INC | MOption exercise Restricted Stock Unitderivative | -10,002 | $0.00 | $0 | 19,998 | Feb 11, 2025 |
Questions about James Karrels
Answered from the filings on this page, as of the latest one.
Is James Karrels buying or selling?
James Karrels has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did James Karrels's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James Karrels has 0.
Where does James Karrels file Form 4?
James Karrels has filed Form 4 at MGNX (MACROGENICS INC) as SVP and CFO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.